Fig. 3
From: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
PD-1 and PD-L1 expression by T cells and osteosarcoma cell line xenografts. a Flow cytometry analysis of PD-1 expression on tumor-infiltrating lymphocytes (TILs) in osteosarcoma 143B cell line xenografts on day 35 post-GD2-BsAb treatment. b Flow cytometry analyses of human CD3(+) T cells and human PD-1 expression by CD3(+) T cells in peripheral blood after GD2-BsAb or HER2-BsAb treatment. c IHC staining and flow cytometry analysis of human PD-L1 in osteosarcoma 143B xenografts. PD-L1 expression levels were quantified using geometric MFI (MFI)